scholarly journals A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

2022 ◽  
Vol 33 ◽  
Author(s):  
Junsik Park ◽  
Myong Cheol Lim ◽  
Jae-Kwan Lee ◽  
Dae Hoon Jeong ◽  
Se Ik Kim ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Phase Ii Study ◽  
Parp Inhibitor ◽  
Gynecologic Oncology ◽  
Recurrent Ovarian Cancer ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Platinum Sensitive ◽  
Previously Treated

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

2015 ◽  
Vol 139 (1) ◽  
pp. 59-62 ◽  
Author(s):  
Haller J. Smith ◽  
Christen L. Walters Haygood ◽  
Rebecca C. Arend ◽  
Charles A. Leath ◽  
J. Michael Straughn
Keyword(s):  
Ovarian Cancer ◽  
Cost Effectiveness ◽  
Maintenance Therapy ◽  
Parp Inhibitor ◽  
Recurrent Ovarian Cancer ◽  
Cost Effectiveness Analysis ◽  
Platinum Sensitive ◽  
Effectiveness Analysis

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group

2006 ◽  
Vol 100 (2) ◽  
pp. 385-388 ◽  
Author(s):  
Cheryl A. Brewer ◽  
John A. Blessing ◽  
Robert A. Nagourney ◽  
D. Scott McMeekin ◽  
Shashikant Lele ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document